Potential of 4-(p-toluenesulfonylamide)-4-hydroxychalcone to inhibit the human cytochrome P450 2J2 isoform

详细信息    查看全文

• 作者：Boram Lee (1)
  Wonku Kang (2)
  Jongcheol Shon (1)
  Ki Hun Park (3)
  Kyung-Sik Song (1)
  Kwang-Hyeon Liu (1)
  
• 关键词：CYP2J2 ; cytotoxicity ; drug interactions ; human liver microsomes ; TSAHC
• 刊名：Journal of the Korean Society for Applied Biological Chemistry
• 出版年：2014
• 出版时间：February 2014
• 年：2014
• 卷：57
• 期：1
• 页码：31-34
• 全文大小：177 KB
• 参考文献：1. Chen C, Li G, Liao W, Wu J, Liu L, Ma D et al. (2009) Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo. / J Pharmacol Exp Ther 329, 908-18. CrossRef
  2. Chen C, Wei X, Rao X, Wu J, Yang S, Chen F et al. (2011) Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth. / J Pharmacol Exp Ther 336, 344-55. CrossRef
  3. Freedman RS, Wang E, Voiculescu S, Patenia R, Bassett RL Jr, Deavers M et al. (2007) Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. / Clin Cancer Res 13, 5736-744. CrossRef
  4. Im Y, Kim YW, Song IS, Joo J, Shin JH, Wu Z et al. (2012) Effect of TSHAC on human cytochrome P450 activity, and transport mediated by Pglycoprotein. / J Microbiol Biotechnol 22, 1659-664. CrossRef
  5. Jiang C, Guo J, Wang Z, Xiao B, Lee HJ, Lee EO et al. (2007a) Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. / Breast Cancer Res 9, R77. CrossRef
  6. Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN et al. (2005) Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. / Cancer Res 65, 4707-715. CrossRef
  7. Jiang JG, Fu XN, Chen CL, and Wang DW (2009) Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines. / Ai Zheng 28, 93-6. CrossRef
  8. Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S et al. (2007b) Cytochrome p450 epoxygenase promotes human cancer metastasis. / Cancer Res 67, 6665-674. CrossRef
  9. Kim H, Yoon YJ, Shon JH, Cha IJ, Shin JG, and Liu KH (2006) Inhibitory effects of fruit juices on CYP3A activity. / Drug Metab Dispos 34, 521-23. CrossRef
  10. Lee CA, Jones JP III, Katayama J, Kaspera R, Jiang Y, Freiwald S et al. (2012) Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. / Drug Metab Dispos 40, 943-51. CrossRef
  11. Lee SA, Kim YM, Kwak TK, Kim HJ, Kim S, Ko W et al. (2009) The extracellular loop 2 of TM4SF5 inhibits integrin alpha2 on hepatocytes under collagen type I environment. / Carcinogenesis 30, 1872-879. CrossRef
  12. Lee SA, Lee MS, Ryu HW, Kwak TK, Kim H, Kang M et al. (2011) Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib. / Cancer Biol Ther 11, 330-36. CrossRef
  13. Liu KH (2011) Screening of Potential Anticancer Compounds from Marketed Drugs: Aripiprazole, Haloperidol, Miconazole, and Terfenadine Inhibit Cytochrome P450 2J2. / J Life Sci 21, 1558-564. CrossRef
  14. Liu KH, Kim MG, Lee DJ, Yoon YJ, Kim MJ, Shon JH et al. (2006) Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. / Drug Metab Dispos 34, 1793-797. CrossRef
  15. Liu KH, Lee YM, Shon JH, Kim MJ, Lee SS, Yoon YR et al. (2004) Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. / Xenobiotica 34, 429-38. CrossRef
  16. Matsumoto S, Hirama T, Kim HJ, Nagata K, and Yamazoe Y (2003) In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. / Xenobiotica 33, 615-23. CrossRef
  17. Matsumoto S, Hirama T, Matsubara T, Nagata K, and Yamazoe Y (2002) Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. / Drug Metab Dispos 30, 1240-245. CrossRef
  18. Matsumoto S and Yamazoe Y (2001) Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. / Br J Clin Pharmacol 51, 133-42. CrossRef
  19. Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J et al. (2013) Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors. / Drug Metab Dispos 41, 60-1. CrossRef
  20. Segel IH (1975) In / Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. Wiley Classics Library, USA.
  21. Seo KA, Kim H, Ku HY, Ahn HJ, Park SJ, Bae SK et al. (2008) The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. / Chem Biol Interact 174, 141-46. CrossRef
  22. Seo WD, Ryu YB, Curtis-Long MJ, Lee CW, Ryu HW, Jang KC et al. (2010) Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. / Eur J Med Chem 45, 2010-017. CrossRef
  23. Waldrop GL (2009) A qualitative approach to enzyme inhibition. / Biochem Mol Biol Educ 37, 11-5. CrossRef
  24. Wu S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. / J Biol Chem 271, 3460-468. CrossRef
  25. Wu Z, Lee BR, Song KS, and Liu KH (2013a) Inhibitory Potential of Thelephoric Acid on CYP2J2 Activities in Humna Liver Microsomes. / J Life Sci 23, 1126-132. CrossRef
  26. Wu Z, Lee D, Joo J, Shin JH, Kang W, Oh S et al. (2013b) CYP2J2 and CYP2C19 Are the Major Enzymes Responsible for Metabolism of Albendazole and Fenbendazole in Human Liver Microsomes and Recombinant P450 Assay Systems. / Antimicrob Agents Chemother 57, 5448-456. CrossRef
  27. Yoon YJ and Liu KH (2011) Potential of Hydroxyebastine and Terfenadine Alcohol to Inhibit the Human Cytochrome P450 2J2 Isoform. / J. Korean Soc Appl Biol Chem 54, 659-66. CrossRef
  
• 作者单位：Boram Lee (1)
  Wonku Kang (2)
  Jongcheol Shon (1)
  Ki Hun Park (3)
  Kyung-Sik Song (1)
  Kwang-Hyeon Liu (1)
  
  1. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, 702-701, Republic of Korea
  2. College of Pharmacy, Yeungnam University, Kyoungbuk, 712-749, Republic of Korea
  3. Division of Applied Life Science, Gyeongsang National University, Jinju, 660-701, Republic of Korea
  
• ISSN：2234-344X

文摘

Human CYP2J2 isoform, the only member of the human CYP2J subfamily, is also over-expressed in human liver carcinoma tissues and hepatocarcinoma cells, and promotes tumor growth and proliferation. 4-(p-Toluenesulfonylamide)-4-hydroxychalcone (TSAHC) is a synthetic sulfonylamino chalcone compound, which has anti-cancer effect. Inhibitory potential of a promising anti-cancer agent TSAHC against CYP2J2 activity was evaluated using human liver microsomes. TSAHC inhibited CYP2J2-mediated astemizole O-demethylation activity with K i value of 2.03±0.40 μM in a competitive mode, suggesting that TSAHC is a potential candidate for further evaluation for its CYP2J2 targeting anti-cancer activities. Studies are presently underway to estimate TSAHC as potential therapeutic agent for cancer.